| Specialty Retail Industry | Consumer Discretionary Sector | Toru Kimura CEO | OTC PINK Exchange | JP3495000006 ISIN |
| JP Country | 4,980 Employees | - Last Dividend | - Last Split | - IPO Date |
Sumitomo Pharma Co., Ltd., originally known as Sumitomo Dainippon Pharma Co., Ltd., underwent a name change in April 2022 and is well established in the pharmaceutical industry. The company, rooted in a rich history dating back to 1897, has expanded its operations beyond its headquarters in Osaka, Japan, to achieve a global footprint. This expansion encompasses key markets in North America, China, and various international locations. As a prominent player in the pharmaceutical sector, Sumitomo Pharma is committed to the discovery, development, and distribution of a wide range of products aimed at improving human and animal health. Its comprehensive portfolio includes pharmaceuticals, food ingredients and additives, veterinary medicines, and more. The company's significant role in the pharmaceutical industry is further evidenced by its strategic partnerships and collaborations with research institutions such as Keio University, RIKEN, Kyoto University, and industry counterparts like Otsuka Pharmaceutical Co., Ltd., and Roivant Sciences Ltd. Operating under the umbrella of Sumitomo Chemical Company, Limited, Sumitomo Pharma adheres to its mission of enhancing healthcare through innovation.
Sumitomo Pharma Co., Ltd. boasts a diverse array of products and services across several categories, underscoring its extensive contribution to the pharmaceutical and healthcare industry.